This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Amgen (AMGN) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Amgen (AMGN) closed at $260.64 in the latest trading session, marking a +0.52% move from the prior day.
Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Amgen (AMGN) closed at $259.30 in the latest trading session, marking a -1.28% move from the prior day.
3 Top Dividend Stocks to Maximize Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?
by Ahan Chakraborty
NVO stock declines after a recent obesity study setback and intense competition from market rivals but offers long-term growth potential.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Here's Why Amgen (AMGN) Gained But Lagged the Market Today
by Zacks Equity Research
The latest trading day saw Amgen (AMGN) settling at $264, representing a +0.24% change from its previous close.
NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III
by Zacks Equity Research
Novo Nordisk stock slumps as the 22.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in a phase III study misses its guidance of 25%.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Twist Bioscience (TWST) Surges 9.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Lilly's Zepbound Receives FDA Approval for Sleep Apnea
by Zacks Equity Research
FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.
Can Dow Jones ETF Reverse From the Worst Losing Streak in 50 Years?
by Sanghamitra Saha
The Dow Jones ETF has recorded the longest losing streak since 1978. Can it reverse the trend in 2025?
Dow on a Record Losing Streak: Should You Buy its ETF?
by Sweta Killa
The Dow Jones has been on its worst losing streak in nearly 50 years. Should you buy its ETF for 2025?
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Amgen (AMGN) Stock Moves -0.21%: What You Should Know
by Zacks Equity Research
In the most recent trading session, Amgen (AMGN) closed at $265.95, indicating a -0.21% shift from the previous trading day.
Why Amgen (AMGN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Amgen (AMGN) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Amgen (AMGN) reachead $273.41 at the closing of the latest trading day, reflecting a -0.85% change compared to its last close.
Here's Why Amgen (AMGN) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
by Zacks Equity Research
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
The Zacks Analyst Blog Eli Lilly, Novo Nordisk's Amgen and Viking Therapeutics
by Zacks Equity Research
Eli Lilly, Novo Nordisk's Amgen and Viking Therapeutics are included in this Analyst Blog.